Breaking News Instant updates and real-time market news.

DE

Deere

$176.91

0.26 (0.15%)

, AVX

AVX

$15.05

0.07 (0.47%)

09:02
11/27/19
11/27
09:02
11/27/19
09:02

Fly Intel: Pre-market Movers

HIGHER: AVX (AVX), up 35% after Kyocera announced that it has made a proposal to a special committee of the board of AVX to acquire all outstanding shares of common stock of the company not owned by Kyocera for $19.50 per share in cash... Under Armour (UA), up 4% after Raymond James analyst Matthew McClintock upgraded shares to Strong Buy from Outperform with an unchanged price target of $30, representing 67% upside. The analyst has become more comfortable with the company's risk/return profile, particularly regarding execution risk and valuation. UP AFTER EARNINGS: Box (BOX), up 3%... Veeva (VEEV), up 3%... HP Inc. (HPQ), up 2%. DOWN AFTER EARNINGS: Deere (DE), down 4%... Guess (GES), down 5%. ALSO LOWER: Akerna (KERN), down 5% after appointing Ashesh Shah CTO. The appointment is effective upon the closing of Akerna's deal to take a majority stake in solo sciences... BrightView (BV), down 3% after Stifel analyst Shlomo Rosenbaum downgraded the stock to Hold from Buy with a price target of $17, down from $19. The analyst points to the company's "erratic performance" over the past year, its "inherent lack of visibility" due to weather related items, and its free cash flow uncertainty due to the Development segment's subprime contractor position.

DE

Deere

$176.91

0.26 (0.15%)

AVX

AVX

$15.05

0.07 (0.47%)

UA

Under Armour

$16.47

0.8 (5.11%)

UAA

Under Armour

$18.01

0.65 (3.74%)

BOX

Box

$16.71

0.23 (1.40%)

VEEV

Veeva

$159.25

2.21 (1.41%)

HPQ

HP Inc.

$20.07

-0.085 (-0.42%)

GES

Guess

$19.12

0.67 (3.63%)

KERN

Akerna

$7.54

1.44 (23.61%)

BV

BrightView

$16.34

-0.335 (-2.01%)

  • 27

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 09

    Dec

  • 11

    Dec

DE Deere
$176.91

0.26 (0.15%)

11/14/19
BOFA
11/14/19
NO CHANGE
BOFA
Stanley Black & Decker upgrade, Deere downgrade among BofA Industrials changes
BofA Merrill Lynch analyst Ross Gilardi made a number of changes in his Industrial Machinery ratings, including three upgrades and two downgrades, as he contends cyclical rotation is likely to persist into 2020. Lead indicators have started to inflect positively, but, in retrospect, he now thinks he was "a little too early" with his pro-cyclical rotation thesis earlier in the year, the analyst said in his sector note. With that view in mind, he upgraded Stanley Black & Decker (SWK) to Buy from Underperform, raised PACCAR (PCAR) and Allison Transmission (ALSN) both to Buy from Neutral, and downgraded Deere (DE) and H&E Equipment (HEES) each to Neutral from Buy. He noted that record defensive-to-cyclical valuation premiums have begun to shrink and said that if there is a de-escalation in China trade tensions, even in a light capital spending environment, he sees the stage being set for a restocking-driven recovery in Spring 2020.
11/14/19
BOFA
11/14/19
DOWNGRADE
BOFA
Neutral
Deere downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill downgraded Deere to Neutral from Buy.
11/25/19
11/25/19
NO CHANGE
Target $200

Buy
Deere price target raised to $200 from $165 at Citi
Citi analyst Timothy Thein raised his price target for Deere to $200 from $165 after visiting large agriculture dealers spread across wide parts of the Corn Belt. Feedback was largely in-line with expectations, and points to 0%-5% large ag growth in fiscal 2020, Thein tells investors in a research note. Given the relatively low current volume levels, none of the U.S. dealers expect to go backwards in 2020, but few see catalysts in place that would drive significant near-term upside, adds the analyst. He sees "attractive risk-adjusted upside" for Deere and keeps a Buy rating on the shares.
11/25/19
JPMS
11/25/19
NO CHANGE
Target $140
JPMS
Underweight
Deere sentiment too bullish into earnings report, says JPMorgan
JPMorgan analyst Ann Duignan says Deere sentiment appears too bullish into the company's fiscal Q4 results on Wednesday. With corn exports down ~60% marketing year-to-date and soybeans about to face new crop competition from Brazil, it is difficult to see how management can present an upbeat fundamental outlook, Duignan tells investors in a pre-earnings research note. With the stock up 23% since the company's Q3 results in August, the analyst reiterates an Underweight rating on Deere with a $140 price target.
AVX AVX
$15.05

0.07 (0.47%)

07/11/19
STFL
07/11/19
NO CHANGE
Target $15
STFL
Hold
Vishay price target lowered to $15 after pre-announcement at Stifel
After Vishay (VSH) pre-announced June quarter sales and gross margins that came below its previous guidance, citing weaker demand, primarily from distribution, Stifel analyst Matthew Sheerin said he thinks the news "should come as no surprise to investors" considering the recent negative tone from several component suppliers and distributors. However, the magnitude of Vishay's miss reflects a deeper correction and increased pricing pressure, said Sheerin, who thinks the correction could last well into the first half 2020. Given the warning, he lowered his estimates and cut his price target on Vishay shares to $15 from $18 and keeps a Hold rating on the stock. Sheerin added that he sees risks to estimates for a number of component suppliers, particularly those with high exposure to distribution, such as AVX (AVX), Kemet (KEM) and Littelfuse (LFUS), and to distributors Arrow Electronics (ARW) and Avnet (AVT).
UA Under Armour
$16.47

0.8 (5.11%)

11/25/19
JEFF
11/25/19
NO CHANGE
Target $22
JEFF
Buy
Meetings reinforce Jefferies' confidence Under Armour 'ready to play offense'
Jefferies analyst Randal Konik said his recent meetings with Under Armour CEO Kevin Plank and incoming CEO Patrik Frisk left him confident that the company is well positioned for long-term growth and margin expansion and "ready to play offense again!" The company is becoming a better-run enterprise, with "clean" inventories, a shortened go-to-market process and enhanced design capabilities while its product roadmap looks "compelling," Konik tells investors. He has a Buy rating and $22 price target on Under Armour shares.
11/05/19
11/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Buy from Conviction Buy at Goldman Sachs and to Neutral from Outperform at Baird. 2. Hudson (HUD) downgraded to Underperform from Neutral at BofA/Merrill with analyst Marisa Sullivan saying after a "disappointing" set of Q3 results and Q4 guidance, she sees an "increasingly uncertain" outlook for the company's core business despite the contributions being made from the OHM and Brookstone acquisitions. 3. Stryker (SYK) downgraded to Equal Weight from Overweight at Barclays with analyst Kristen Stewart saying while Stryker remains a "strong company fundamentally," the stock's performance over the next year is likely to be restrained by the outstanding Wright Medical Group (WMGI)m which is not expected to close until Q3 of 2020. 4. U.S. Steel (X) downgraded to Hold from Buy at Argus with analyst David Coleman saying its Q3 earnings came in "significantly short" relative to his estimates. 5. Prudential (PRU) downgraded to Market Perform from Outperform at Wells Fargo with analyst Elyse Greenspan saying the company's quarterly EPS of $3.22 handily beat estimates, but this was the second quarter in a row where earnings have been re-based lower. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/19
RAJA
11/27/19
UPGRADE
Target $30
RAJA
Strong Buy
Raymond James upgrades Under Armour to Strong Buy with 67% potential upside
Raymond James analyst Matthew McClintock upgraded Under Armour (UAA) to Strong Buy from Outperform with an unchanged price target of $30, representing 67% upside. The shares closed Tuesday up 63c to $17.99. The analyst has become more comfortable with the company's risk/return profile, particularly regarding execution risk and valuation. Under Armour is ahead of plan with new product already available at wholesale partners and selling through at higher level, McClintock tells investors in a research note. Further, after speaking to investors, the analyst believes the ongoing communication between Under Armour and the Securities and Exchange Commission/Department of Justice is likely less to be an overhang to the stock than he originally feared.
11/27/19
RAJA
11/27/19
UPGRADE
Target $30
RAJA
Strong Buy
Under Armour upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Matthew McClintock upgraded Under Armour (UAA) to Strong Buy from Outperform with an unchanged price target of $30.
UAA Under Armour
$18.01

0.65 (3.74%)

11/12/19
LEHM
11/12/19
INITIATION
Target $19
LEHM
Equal Weight
Under Armour initiated with an Equal Weight at Barclays
Barclays analyst Adrienne Yih initiated coverage of Under Armour with an Equal Weight rating and $19 price target. The analyst likes the company's "significant global brand awareness and opportunities in under-penetrated target markets, categories, and geographies, but also cites the recent news regarding the ongoing inquiries into its revenue recognition accounting from the DoJ and the SEC.
BOX Box
$16.71

0.23 (1.40%)

11/12/19
JMPS
11/12/19
DOWNGRADE
JMPS
Market Perform
Box downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Erik Suppiger downgraded Box to Market Perform from Outperform. The analyst attributes the rating change to concerns that after the challenging October quarter, the pipeline of the company's business has slowed. While his earnings forecasts are moving higher to reflect the company's cost-cutting actions, Suppiger adds that with enterprise value to expected 2021 revenue at a 3.2-times multiple, Box shares are "fairly valued".
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CSX (CSX) downgraded to Hold from Buy at Deutsche Bank. 2. Eaton (ETN) downgraded to Hold from Buy at HSBC. 3. Amneal Pharmaceuticals (AMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Christopher Schott saying while some of the challenges facing the company appear fixable, like supply penalties and plant utilization, many appear fundamental, a function of the evolving dynamics in the U.S. generics market. 4. Albemarle (ALB) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan saying with lithium prices falling below historical levels, global lithium suppliers may have to reduce output and wait for demand to catch up. 5. Box (BOX) downgraded to Market Perform from Outperform at JMP Securities with analyst Erik Suppiger citing concerns that after the challenging October quarter, the pipeline of the company's business has slowed. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/19
WELS
11/27/19
NO CHANGE
Target $22
WELS
Outperform
Box price target raised to $22 from $20 at Wells Fargo
Wells Fargo analyst Philip Winslow noted that Box reported Q3 revenue, margins, EPS, and billings that all beat consensus and raised its full-year guidance, adding that the company showed execution improvements in the quarter. Winslow, who maintains a positive view on Box's positioning and product portfolio, keeps an Outperform rating on the shares and raised his price target on the stock to $22 after revising his FY20 estimates on the heels of the Q3 report.
11/12/19
JMPS
11/12/19
DOWNGRADE
JMPS
Market Perform
Box downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Erik Suppiger downgraded Box to Market Perform from Outperform.
VEEV Veeva
$159.25

2.21 (1.41%)

10/03/19
SPHN
10/03/19
NO CHANGE
Target $185
SPHN
Overweight
Veeva leaving room for investments or M&A with 2025 targets, says Stephens
Stephens analyst James Rutherford said some investors may have expected a more aggressive margin outlook than the five-year 35%+ adjusted EBIT margins guidance that Veeva announced yesterday at its investor day, but he believes the company is leaving itself room to make incremental investments and/or pursue additional strategic M&A that could help it achieve its $3B annual revenue target more quickly. Rutherford, who continues to see Veeva as one of the best positioned companies in its industry, keeps an Overweight rating and $185 price target on the shares.
09/26/19
RAJA
09/26/19
UPGRADE
Target $180
RAJA
Outperform
Veeva pullback offers 'attractive' entry point, says Raymond James
Raymond James analyst Brian Peterson upgraded Veeva Systems to Outperform from Market Perform with a $180 price target ahead of the company's analyst day next week. The recent pullback provides an attractive entry point into the shares, Peterson tells investors in a research note. Specifically, Peterson says he expects management to provide incremental detail on key growth areas including EDC and efforts outside of life sciences, which could be reaching an inflection point, and says that with each of these emerging growth opportunities equating to a $1B+ TAM, this should give investors increasing confidence in the durability of Veeva's growth profile.
10/03/19
WBLR
10/03/19
NO CHANGE
WBLR
Outperform
Veeva introduced 'bullish' 2025 sales target of $3B, says William Blair
William Blair analyst Bhavan Suri says Veeva Systems management yesterday introduced "bullish" long-term targets, including a $3B revenue run-rate goal by calendar 2025, indicating 19% annual growth, largely reflective of growth within life sciences offerings. Increased "agility and speed to market capabilities," as well as the continued adoption of Veeva's early stage products, will lead to "multiple years" of greater than 20% revenue growth with "best-in-class" operating margins in excess of 35%, Suri tells investors in a research note. He reiterates an Outperform rating on the shares.
10/03/19
GUGG
10/03/19
NO CHANGE
GUGG
Buy
Veeva right to invest, but first reaction likely negative, says Guggenheim
After Veeva CFO Tim Cabral announced a new long-term goal of 19% revenue CAGR through 2025 to $3B and a 2025 target for 35%+ EBIT margins at the company's investor day meeting, Guggenheim analyst Ken Wong said he expects the initial investor reaction to the new 5-year targets to be mildly negative and for skeptics to "zero in" on the margins target being seen as a step down from the 38% levels projected for FY20. However, Wong said the growth targets are better than he expected, thinks the margins view feels "conservative" and expects any negativity to be short lived. The analyst, who views the company's elevated investments as appropriate given Veeva's product roadmap, keeps a Buy rating on the stock.
HPQ HP Inc.
$20.07

-0.085 (-0.42%)

11/25/19
JPMS
11/25/19
NO CHANGE
Target $19
JPMS
Neutral
HP Inc. risks skewed to downside near-term, says JPMorgan
JPMorgan analyst Paul Coster says that while HP Inc.'s (HPQ) "likely frosty" response to what could evolve into a hostile bid from Xerox (XRX) is probably the main focus of investors into the fiscal Q4 results, the stock's near-term risks are skewed to the downside. The print itself is unlikely to strengthen HP's case for independence if continued declines in the high-margin printer segment shift sentiment in favor of "urgent cost-cutting of the kind already instituted by Xerox," Coster tells investors in a research note. He believes a "bad print" could reinforce the view that HP's personal and office printer business is in secular decline, whether or not combined with that of Xerox. Coster keeps an Underweight rating on HP Inc. shares with a $19 price target.
11/25/19
LOOP
11/25/19
NO CHANGE
Target $47
LOOP
Buy
Xerox price target raised to $47 from $42 at Loop Capital
Loop Capital analyst Ananda Baruah raised his price target on Xerox (XRX) to $47 and kept his Buy rating, saying that regardless of the outcome of its efforts to acquire HP Inc (HPQ), his recent discussion with its management has made him more bullish on the company's prospects. The analyst sees the new management committed to "creativity, sophistication, and velocity for creating both company and equity value", adding that at 9.3-times enterprise value to expected free cash flow, the stock offers "inherent" free cash flow value.
11/27/19
WELS
11/27/19
NO CHANGE
Target $22
WELS
Market Perform
HP Inc. commercial PC performance stronger than expected, says Wells Fargo
Wells Fargo analyst Aaron Rakers said HP Inc. (HPQ) delivered what he thinks investors will view as net-positive quarterly results on printing supplies revenue that was roughly in line with his forecast along with strength in the commercial PC segment. Of note, HP did not provide comments on Xerox's (XRX) hostile takeover efforts, Rakers pointed out. He maintains a Market Perform rating on HP shares and increased his price target on the stock to $22 from $20 after the company's guidance raise.
11/22/19
DBAB
11/22/19
NO CHANGE
DBAB
Hold
HP, Xerox deal 'continues to be in play,' says Deutsche Bank
While admitting there is a bit of a "he said, she said" dynamic playing out, Deutsche Bank analyst Jeriel Ong sees the interaction between HP Inc. (HPQ) and Xerox (XRX) as a "positive indicator that some kind of a deal continues to be in play." The analyst, who says he has no incremental information to discern whether Xerox's claim that HP has not agreed to mutual diligence as a delay tactic holds merit or not, believes that a combined company makes more sense with HP as the acquirer rather than the target.
GES Guess
$19.12

0.67 (3.63%)

11/26/19
JEFF
11/26/19
NO CHANGE
Target $38
JEFF
Buy
Zumiez price target raised to $38 from $34 at Jefferies
Jefferies analyst Janine Stichter said she finds that many of the larger retro and streetwear brands are seeing search interest track flat to down with weakened social media engagement, which she views as a signal that the the cycle is now past peak, although the category is still broadly healthy. Even with a fairly heavy reliance on Vans, Zumiez (ZUMZ) is sufficiently diverse to weather a deceleration in the retro cycle and data also suggests a major resurgence in skateboards, which is positive for Zumiez, said Stichter, who raised her price target on the stock to $38 from $34 and keeps a Buy rating on the shares. Despite the broader downtrend in the retro brand cycle, he checks also indicate that the Guess (GES) brand is "in the earlier stages of capitalizing on its status as a retro 90s brand," added Stichter.
03/21/19
JEFF
03/21/19
NO CHANGE
Target $24
JEFF
Buy
Guess in penalty box but fundamentals healthy, says Jefferies
While Guess shares will be in the penalty box near-term as an inventory overhang weighs on margins, its fundamentals remain healthy, Jefferies analyst Janine Stichter tells investors in a research note. The analyst expects CEO Carlos Alberini's return to be a positive catalyst for Guess and that his first earnings call as CEO was a strong one. Significant market share potential remains in Europe and Asia for Guess while North America appears to be gaining momentum, says Stichter. She keeps a Buy rating on the shares with a $24 price target.
06/27/19
JEFF
06/27/19
NO CHANGE
JEFF
Jefferies reiterates Buys on Guess, American Eagle after female survey
After surveying 600 female consumers to analyze changes in brand momentum, Jefferies analyst Janine Stichter reiterates Buy ratings on both Guess (GES) and American Eagle (AEO). Results are favorable for Guess, which is seeing an increase in brand awareness and improved purchasing intent, Stichter tells investors in a research note. For American Eagle, investments in the store experience are translating into improved customer satisfaction, while Aerie also continues to score well across all key metrics, adds the analyst.
07/22/19
JEFF
07/22/19
NO CHANGE
Target $24
JEFF
Buy
Guess near-term results may be better than what's priced in, says Jefferies
Geolocation data suggest "significant" improvement in June traffic levels for Guess, Jefferies analyst Janine Stichter tells investors in a research note. Further, web traffic data show rising penetration of Guess's shopping cart and checkout page, suggesting improving conversion, adds the analyst. As a result, she believes the company's near-term performance may not be as challenging as the market is pricing in. In addition, Guess's longer term opportunity "remains very much intact," says Stichter. The analyst keeps a Buy rating on the shares with a $24 price target.
KERN Akerna
$7.54

1.44 (23.61%)

BV BrightView
$16.34

-0.335 (-2.01%)

11/26/19
STFL
11/26/19
DOWNGRADE
Target $17
STFL
Hold
BrightView downgraded to Hold from Buy at Stifel
Stifel analyst Shlomo Rosenbaum downgraded BrightView to Hold from Buy with a price target of $17, down from $19. The analyst points to the company's "erratic performance" over the past year, its "inherent lack of visibility" due to weather related items, and its free cash flow uncertainty due to the Development segment's subprime contractor position. Rosenbaum further contends that his investment story on BrightView stock has "devolved" to one where the management has "finally" set achievable guidance, which he states is not a sufficiently compelling long-term thesis.
11/26/19
STFL
11/26/19
DOWNGRADE
STFL
Hold
BrightView downgraded to Hold from Buy at Stifel
11/21/19
JEFF
11/21/19
INITIATION
Target $23
JEFF
Buy
BrightView assumed with a Buy at Jefferies
Jefferies analyst Hamzah Mazari assumed coverage of BrightView with a Buy rating and $23 price target.
11/21/19
JEFF
11/21/19
INITIATION
JEFF
Jefferies initiates Diversifed Services sector
Jefferies analyst Hamzah Mazari initiated select names across Diversified Services as part of his broader research note covering the Business Services industry. The analyst has a Buy rating on Cintas (CTAS) with a $308 price target, Bright Horizons (BFAM) with a $177 price target, BrightView (BV) with a $23 price target, and ServiceMaster (SERV) with a $43 price target. Mazari likes the M&A potential and employment decoupling at Cintas, revenue growth visibility and cross selling opportunity at Bright Horizons, low organic growth expectations and free cash flow potential at BrightView, and underappreciated international growth opportunity at ServiceMaster. The analyst also rates Aramark (ARMK), H&R Block (HRB), and Rollins (ROL) at Hold with respective $49, $28, and $38 price targets, noting that Aramark expectations are "too high" on activist involvement, H&R Block suffers from lack of catalysts, and Rollins' M&A potential appears to be "baked in" to its valuation.

TODAY'S FREE FLY STORIES

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.